654 filings
Page 2 of 33
6-K
6usqn9coy
2 Aug 23
Immutep Receives Positive Scientific Advice from European Medicines Agency
12:00am
6-K
ci9l6ozqbolp
31 Jul 23
Immutep Quarterly Activities Report & Appendix 4C
9:12pm
6-K
98a6iiggvj49v
28 Jul 23
Current report (foreign)
6:31am
6-K
qyhzo2o f0m8
27 Jun 23
Immutep Secures Third United States Patent for Eftilagimod Alpha
7:08pm
6-K
u8ddp4viz22cevlxs
20 Jun 23
Current report (foreign)
6:45pm
6-K
8ymj7
5 Jun 23
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous
8:55pm
6-K
5ypom9 7nshbs
2 Jun 23
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
6:19pm
6-K
panvo62 3o
30 May 23
Current report (foreign)
8:18pm
6-K
7fx7n2mht6s87hm
26 May 23
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
6:10am
6-K
7ncukw2z1vrwka
25 May 23
Current report (foreign)
6:06am
6-K
d0yxr43 yh5r0v0soczg
24 May 23
Immutep Announces Promising New Clinical Data from Triple Combination
6:54pm
6-K
t8ozwyw4k49 cgb5q
17 May 23
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial
6:06am
6-K
t20mvvgp85wi50k
16 May 23
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development
6:09am
EFFECT
3fhomgi0bfn1i1xptv
8 May 23
Notice of effectiveness
12:15am
CORRESP
0kmcbl kdygvaya9zn5
3 May 23
Correspondence with SEC
12:00am
UPLOAD
ppdik3kk2wgdiv493
2 May 23
Letter from SEC
12:00am
6-K
8bwhq8qkuhzicqd2k
2 May 23
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating
12:00am
6-K
84ok8d80 qizjlq
28 Apr 23
Immutep Quarterly Activities Report & Appendix 4C
6:10am
F-3
ihum 9uvfy9qj
28 Apr 23
Shelf registration (foreign)
6:09am
6-K
yqkq7 hpj
17 Apr 23
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
9:09pm